---
figid: PMC4700229__tlcr-04-06-752-f1
figlink: /pmc/articles/PMC4700229/figure/f1/
number: Figure 1
caption: Interactions between immunotherapy and targeted therapy. T-cell activation
  is a consequence of two simultaneous processes, the expression of protein B7 and
  antigen presentation by antigen presenting cells (APCs) to T-cell receptor. Mitogen-activated
  protein kinase (MAPK) signaling pathway is responsible for differentiation, proliferation,
  and survival of the cells. Mutations on particular stages of the pathway lead to
  uncontrolled enhancements of these processes. The abrogation of the MAPK cascade
  causes cell death and the inhibition of activated T-cells occurs as a result of
  the expression of CTLA-4 and PD-1 receptor on T-cells’ surface. The combination
  of both theoretically improves treatment success.
pmcid: PMC4700229
papertitle: 'Immunotherapy meets targeted therapy: will this team end the war against
  cancer?.'
reftext: Daniela Morales-Espinosa, et al. Transl Lung Cancer Res. 2015 Dec;4(6):752-755.
pmc_ranked_result_index: '33196'
pathway_score: 0.9665157
filename: tlcr-04-06-752-f1.jpg
figtitle: Interactions between immunotherapy and targeted therapy
year: '2015'
organisms: Homo sapiens
ndex: 5b6aa1eb-ded0-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4700229__tlcr-04-06-752-f1.html
  '@type': Dataset
  description: Interactions between immunotherapy and targeted therapy. T-cell activation
    is a consequence of two simultaneous processes, the expression of protein B7 and
    antigen presentation by antigen presenting cells (APCs) to T-cell receptor. Mitogen-activated
    protein kinase (MAPK) signaling pathway is responsible for differentiation, proliferation,
    and survival of the cells. Mutations on particular stages of the pathway lead
    to uncontrolled enhancements of these processes. The abrogation of the MAPK cascade
    causes cell death and the inhibition of activated T-cells occurs as a result of
    the expression of CTLA-4 and PD-1 receptor on T-cells’ surface. The combination
    of both theoretically improves treatment success.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K1
  - FGFR2
  - FGFR4
  - FGFR3
  - PIK3CA
  - RAF1
  - APC
  - PIK3R4
  - FGFR1
  - PIK3CB
  - PIK3CD
  - BRAF
  - FGFRL1
  - MTOR
  - PDCD1
  - PIK3R5
  - SHC4
  - CD80
  - PIK3R6
  - CTLA4
  - PDGFRA
  - EGFR
  - CD86
  - ARAF
  - CD274
  - PIK3R3
  - PDGFRB
  - MAPK3
  - MAPK1
  - GRB2
  - SHC1
  - SHC2
  - SOS2
  - MAP2K2
  - PDCD1LG2
  - AKT1
  - AKT2
  - SHC3
  - HRAS
  - AKT3
  - NRAS
  - PIK3CG
  - SOS1
  - KRAS
  - Selumetinib
  - Dabrafenib
  - Cobimetinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: (e.g.,PDGFR,FGFR,EGFR)
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: (e.g.,PDGFR,FGFR,EGFR)
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: (e.g.,PDGFR,FGFR,EGFR)
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: APC
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: (e.g.,PDGFR,FGFR,EGFR)
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: (e.g.,PDGFR,FGFR,EGFR)
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC4
  entrez: '399694'
- word: B7-1/B7-2
  symbol: B7-1
  source: hgnc_alias_symbol
  hgnc_symbol: CD80
  entrez: '941'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: CTLA-4
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: (e.g.,PDGFR,FGFR,EGFR)
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: (e.g.,PDGFR,FGFR,EGFR)
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: B7-1/B7-2
  symbol: B7-2
  source: hgnc_alias_symbol
  hgnc_symbol: CD86
  entrez: '942'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PD-L1/B7-H1
  symbol: B7-H1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: PD-L1/B7-H1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: (e.g.,PDGFR,FGFR,EGFR)
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: GRB2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC1
  entrez: '6464'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC2
  entrez: '25759'
- word: SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PD-L2/B7-DC
  symbol: PD-L2
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1LG2
  entrez: '80380'
- word: PD-L2/B7-DC
  symbol: B7-DC
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1LG2
  entrez: '80380'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC3
  entrez: '53358'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
chemicals:
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Cobimetinib
  source: MESH
  identifier: C574276
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
